CSIMarket


Adma Biologics Inc   (ADMA)
Other Ticker:  
 

Adma Biologics Inc

ADMA's Fundamental analysis








Looking into Adma Biologics Inc growth rates, revenue grew by 42.51 % in I. Quarter 2024 from the same quarter a year ago. Ranking at No. 386

Biotechnology & Pharmaceuticals industry recorded deterioration of revenues by -0.98 %

Adma Biologics Inc realized net income compared to net loss a year ago in I. Quarter 2024

More on ADMA's Growth


Adma Biologics Inc
realized net loss in trailing twelve months.

Adma Biologics Inc realized cash outflow of $ -0.1per share in trailing twelve-month period.
Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 8.01.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.85.


More on ADMA's Valuation
 
 Total Debt (Millions $) 131
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 1,102,096
 Net Income/Employee (TTM) $ -14,235
 Receivable Turnover (TTM) 7.78
 Tangible Book Value (Per Share $) 0.63

Adma Biologics Inc
realized net loss in trailing twelve months.

Adma Biologics Inc realized cash outflow of $ -0.1per share in trailing twelve-month period.
Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 8.01.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.85.

Adma Biologics Inc Price to Book Ratio is at 14.7 lower than Indusry Avg. of 774.31. and higher than S&P 500 Avg. of 0.01

More on ADMA's Valuation

  Market Capitalization (Millions $) 2,260
  Shares Outstanding (Millions) 236
  Employees 256
  Revenues (TTM) (Millions $) 282
  Net Income (TTM) (Millions $) -4
  Cash Flow (TTM) (Millions $) -24
  Capital Exp. (TTM) (Millions $) -5
  Total Debt (Millions $) 131
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 1,102,096
  Net Income/Employee(TTM) $ -14,235
  Receivable Turnover Ratio (TTM) 7.78
  Tangible Book Value (Per Share $) 0.63

  Market Capitalization (Millions $) 2,260
  Shares Outstanding (Millions) 236
  Employees 256
  Revenues (TTM) (Millions $) 282
  Net Income (TTM) (Millions $) -4
  Cash Flow (TTM) (Millions $) -24
  Capital Exp. (TTM) (Millions $) -5


    ADMA's Profitability Comparisons
Adma Biologics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in I. Quarter 2024 to 26.9 % from 19.06 % in IV. Quarter.

Adma Biologics Inc net profit margin of 21.95 % is currently ranking no. 5 in Biotechnology & Pharmaceuticals industry, ranking no. 40 in Healthcare sector and number 521 in S&P 500.





  Ratio
   Capital Ratio (MRQ) 5.43
  Total Debt to Equity (MRQ) 0.85
  Tangible Leverage Ratio (MRQ) 1.23
  Asset Turnover Ratio (TTM) 0.82
  Inventory Turnover Ratio (TTM) 1.01



Adma Biologics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in I. Quarter 2024 to 26.9 % from 19.06 % in IV. Quarter.

Adma Biologics Inc net profit margin of 21.95 % is currently ranking no. 5 in Biotechnology & Pharmaceuticals industry, ranking no. 40 in Healthcare sector and number 521 in S&P 500.

More on ADMA's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com